All In Biotech

Drug Trial Radar · NCT06312644

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Dec 16, 2024

Primary completion

Jul 11, 2034

Study completion Jul 11, 2034

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.

Conditions

  • Ultomiris-exposed Pregnant/ Postpartum
  • Pregnancy
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Generalized Myasthenia Gravis (gMG)
  • Neuromyelitis Optica Spectrum Disorder (NMOSD)

Interventions

  • UltomirisDrug

    Participants exposed to Ultomiris at any point during the 40 weeks prior to conception (LMP+14 days) or at any point during pregnancy or breastfeeding up to 52 weeks after birth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pregnancy ComplicationsTime frame: Up to 4 weeks post-delivery
  2. Maternal ComplicationsTime frame: Up to 4 weeks post-delivery
  3. Fetal/Infant OutcomesTime frame: In utero through 52 weeks of age after exposure to Ultomiris (in utero or via breastmilk)

Locations

7 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Melbourne, Victoria, Australia · Not yet recruiting

  • Research Site

    Paris, France · Recruiting

  • Research Site

    Essen, Norte-Westfalia, Germany · Recruiting

  • Research Site

    Rome, Italy · Recruiting

  • Research Site

    Seoul, South Korea · Active not recruiting

  • Research Site

    London, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.